• Je něco špatně v tomto záznamu ?

The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial-to-mesenchymal transition

Z. Kahounová, D. Kurfürstová, J. Bouchal, G. Kharaishvili, J. Navrátil, J. Remšík, Š. Šimečková, V. Študent, A. Kozubík, K. Souček,

. 2018 ; 93 (9) : 941-951. [pub] 20170406

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045614

Grantová podpora
NV15-33999A MZ0 CEP - Centrální evidence projektů
NV15-28628A MZ0 CEP - Centrální evidence projektů

The identification of fibroblasts and cancer-associated fibroblasts from human cancer tissue using surface markers is difficult, especially because the markers used currently are usually not expressed solely by fibroblasts, and the identification of fibroblast-specific surface molecules is still under investigation. It was aimed to compare three commercially available antibodies in the detection of different surface epitopes of fibroblasts (anti-fibroblast, fibroblast activation protein α, and fibroblast surface protein). The specificity of their expression, employing fibroblast cell lines and tumor-derived fibroblasts from breast and prostate tissues was investigated. Both the established fibroblast cell line HFF-1 and ex vivo primary fibroblasts isolated from breast and prostate cancer tissues expressed the tested surface markers to different degrees. Surprisingly, those markers were expressed also by permanent cell lines of epithelial origin, both benign and cancer-derived (breast-cell lines MCF 10A, HMLE and prostate-cell lines BPH-1, DU 145, and PC-3). The expression of fibroblast activation protein α increased on the surface of previously described models of epithelial cells undergoing epithelial-to-mesenchymal transition in response to treatment with TGF-β1. To prove the co-expression of the fibroblast markers on cells of epithelial origin, we used freshly dissociated human prostate and breast cancer tissues. The results confirmed the co-expression of anti-fibroblast and fibroblast surface protein on CD31/CD45-negative/EpCAM-positive epithelial cells. In summary, our data support the findings that the tested fibroblast markers are not fibroblast specific and may be expressed also by cells of epithelial origin (e.g., cells undergoing EMT). Therefore, the expression of these markers should be interpreted with caution, and the combination of several epitopes for both positive (anti-fibroblast or fibroblast activation protein α) and negative (EpCAM) identification of fibroblasts from breast and prostate tumor tissues is advised. © 2017 International Society for Advancement of Cytometry.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045614
003      
CZ-PrNML
005      
20240903093516.0
007      
ta
008      
200109s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cyto.a.23101 $2 doi
035    __
$a (PubMed)28383825
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kahounová, Zuzana $u Department of Cytokinetics, Institute of Biophysics of the CAS, v.v.i, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.
245    14
$a The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial-to-mesenchymal transition / $c Z. Kahounová, D. Kurfürstová, J. Bouchal, G. Kharaishvili, J. Navrátil, J. Remšík, Š. Šimečková, V. Študent, A. Kozubík, K. Souček,
520    9_
$a The identification of fibroblasts and cancer-associated fibroblasts from human cancer tissue using surface markers is difficult, especially because the markers used currently are usually not expressed solely by fibroblasts, and the identification of fibroblast-specific surface molecules is still under investigation. It was aimed to compare three commercially available antibodies in the detection of different surface epitopes of fibroblasts (anti-fibroblast, fibroblast activation protein α, and fibroblast surface protein). The specificity of their expression, employing fibroblast cell lines and tumor-derived fibroblasts from breast and prostate tissues was investigated. Both the established fibroblast cell line HFF-1 and ex vivo primary fibroblasts isolated from breast and prostate cancer tissues expressed the tested surface markers to different degrees. Surprisingly, those markers were expressed also by permanent cell lines of epithelial origin, both benign and cancer-derived (breast-cell lines MCF 10A, HMLE and prostate-cell lines BPH-1, DU 145, and PC-3). The expression of fibroblast activation protein α increased on the surface of previously described models of epithelial cells undergoing epithelial-to-mesenchymal transition in response to treatment with TGF-β1. To prove the co-expression of the fibroblast markers on cells of epithelial origin, we used freshly dissociated human prostate and breast cancer tissues. The results confirmed the co-expression of anti-fibroblast and fibroblast surface protein on CD31/CD45-negative/EpCAM-positive epithelial cells. In summary, our data support the findings that the tested fibroblast markers are not fibroblast specific and may be expressed also by cells of epithelial origin (e.g., cells undergoing EMT). Therefore, the expression of these markers should be interpreted with caution, and the combination of several epitopes for both positive (anti-fibroblast or fibroblast activation protein α) and negative (EpCAM) identification of fibroblasts from breast and prostate tumor tissues is advised. © 2017 International Society for Advancement of Cytometry.
650    _2
$a biologické markery $x metabolismus $7 D015415
650    _2
$a nádory prsu $x metabolismus $7 D001943
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a adhezní molekula epiteliálních buněk $x metabolismus $7 D000071858
650    _2
$a epitelové buňky $x metabolismus $7 D004847
650    _2
$a epitelo-mezenchymální tranzice $x fyziologie $7 D058750
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibroblasty $x metabolismus $7 D005347
650    _2
$a želatinasy $x metabolismus $7 D018093
650    _2
$a lidé $7 D006801
650    _2
$a antigeny CD45 $x metabolismus $7 D017493
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a membránové proteiny $x metabolismus $7 D008565
650    _2
$a buňky PC-3 $7 D000078722
650    _2
$a antigeny CD31 $x metabolismus $7 D019408
650    _2
$a nádory prostaty $x metabolismus $7 D011471
650    _2
$a serinové endopeptidasy $x metabolismus $7 D012697
650    _2
$a transformující růstový faktor beta1 $x metabolismus $7 D053773
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kurfürstová, Daniela $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. $7 xx0269558
700    1_
$a Bouchal, Jan $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Kharaishvili, Gvantsa $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Navrátil, Jiří $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. $7 xx0164164
700    1_
$a Remšík, Ján $u Department of Cytokinetics, Institute of Biophysics of the CAS, v.v.i, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic. Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Šimečková, Šárka $u Department of Cytokinetics, Institute of Biophysics of the CAS, v.v.i, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic. Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Študent, Vladimír $u Department of Urology, University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Kozubík, Alois $u Department of Cytokinetics, Institute of Biophysics of the CAS, v.v.i, Brno, Czech Republic. Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Souček, Karel $u Department of Cytokinetics, Institute of Biophysics of the CAS, v.v.i, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic. Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
773    0_
$w MED00013935 $t Cytometry. Part A $x 1552-4930 $g Roč. 93, č. 9 (2018), s. 941-951
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28383825 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20240903093512 $b ABA008
999    __
$a ok $b bmc $g 1483882 $s 1084287
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 93 $c 9 $d 941-951 $e 20170406 $i 1552-4930 $m Cytometry. Part A $n Cytometry A $x MED00013935
GRA    __
$a NV15-33999A $p MZ0
GRA    __
$a NV15-28628A $p MZ0
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace